| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Polyinosinic-polycytidylic acid sodium (Poly(I:C) sodium) is an analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors with the potential to be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. It can directly trigger cancer cells to undergo apoptosis.
| ln Vitro |
Polyinosinic-polycytidylic acid (20 ng/mL; 24 hours; WM793, WM278, WM239A, WM9, and 1205Lu cells) treatment dramatically decreased cell viability in a day, going from 100% of control to 20%–50%. %[1]. Treatment of 1205Lu cells with 200 ng/mL of polyinosinic-polycytidylic acid for 24 hours causes apoptosis in these cells.[1]. Melanoma cells treated with polyinosinic-polycytidylic acid (3 ng/mL; 24 hours; 1205Lu cells) express IFN-β. The stimulation of IFN-β by polyinosinic-polycytidylic acid requires IPS-1 and RIG-I and MDA-5, respectively, as demonstrated by the silencing of these two proteins [1].
In melanoma cells, treatment with polyinosinic-polycytidylic acid (5 ng/mL) for 24 hours revealed the presence of caspase-9 and caspase-8 active subunits [1]. Polyinosinic-polycytidylic acid sodium salt, ready for injection by resuspension in sterile saline at a concentration of 2 mg/mL, heated to 50 °C to guarantee total dissolution and allowed to naturally cool to room temperature to guarantee correct dissolution of double-stranded RNA annealing. Until used, polyinosinic-polycytidylic acid should be kept refrigerated at -20 °C [3]. |
|---|---|
| ln Vivo |
When injected with 1205Lu cells, polyinosinic-polycytidylic acid prevents the formation of tumors in immunodeficient NOD/SCID animals. Mice treated with Polyinosinic-polycytidylic acid showed a 50% reduction in human DNA levels [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: WM793, WM278, WM239A, WM9 and 1205Lu cells Tested Concentrations: 20 ng/mL Incubation Duration: 24 hrs (hours) Experimental Results: Strongly decreased viability from 100% in controls to 20%–50% within 24 hrs (hours). Apoptosis Analysis[1] Cell Types: 1205Lu cells Tested Concentrations: 200 ng/mL Incubation Duration: 24 hrs (hours) Experimental Results: Induced apoptosis in 1205Lu cells. RT-PCR[1] Cell Types: 1205Lu cells Tested Concentrations: 3 ng/mL Incubation Duration: 24 hrs (hours) Experimental Results: Induced IFN-β expression in melanoma cells. Western Blot Analysis[1] Cell Types: 1205Lu cells Tested Concentrations: 5 ng/mL Incubation Duration: 24 hrs (hours) Experimental Results: Revealed active subunits of caspase-9 and caspase-8 in melanoma cells . |
| References |
|
| Molecular Formula |
C19H27N7NAO16P2
|
|---|---|
| Molecular Weight |
694.392277002335
|
| Exact Mass |
694.088
|
| CAS # |
42424-50-0
|
| Related CAS # |
Polyinosinic-polycytidylic acid;24939-03-5;Poly (I:C):Kanamycin (1:1) (sodium);Polyinosinic-polycytidylic acid potassium;31852-29-6
|
| PubChem CID |
137229713
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
45
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
P(=O)(O)(O)OCC1C(C(C(N2C=NC3C(NC=NC2=3)=O)O1)O)O.P(=O)(O)(O)OCC1C(C(C(N2C(N=C(C=C2)N)=O)O1)O)O.[Na]
|
| InChi Key |
GETQKWBYQAUFQM-VRQAYDGLSA-N
|
| InChi Code |
InChI=1S/C10H13N4O8P.C9H14N3O8P.Na/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18);/t4-,6-,7-,10-;4-,6-,7-,8-;/m11./s1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~10 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 6.67 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4401 mL | 7.2006 mL | 14.4011 mL | |
| 5 mM | 0.2880 mL | 1.4401 mL | 2.8802 mL | |
| 10 mM | 0.1440 mL | 0.7201 mL | 1.4401 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
